ALTIMETRIK

AI-Driven Patient Engagement in Pharma

Key Aspects, Challenges, & Real-World Applications

Authored By

Sudhanshu Chaturvedi
Senior Engineering Leader - Lifesciences

Rishabh Tickoo
Marketing Lead - Lifesciences

White Paper

Contents

1. Executive Summary 3
2. Introduction 4
3. Technical Foundations of AI-Driven Patient Engagement 5
4. Implementation Challenges 8
5. Real World Case Studies: AI in Action 13
6. Conclusion 17
7. References 18

Executive Summary

The pharmaceutical industry is undergoing a seismic shift in how it engages patients, driven by the rapid adoption of artificial intelligence (AI). Traditional one-size-fits-all outreach is giving way to AI-powered, omnichannel strategies that deliver personalized, real-time support. These innovations are improving medication adherence and health outcomes while transforming pharma companies from mere drug suppliers into lifelong health partners. This whitepaper provides a deep dive into the AI models, digital infrastructure, and regulatory frameworks enabling this transformation. It also examines implementation challenges – from data privacy, compliance, to integration with electronic health records – and highlights real-world case studies from leaders like **Novartis, GSK,** and **Walgreens,** including how AI is enhancing patient support, including financial co-pay assistance.

What's inside:

- **Improving adherence with personalized AI engagement:** Tailored AI-driven interventions have been shown to improve medication adherence by up to 9.7% in chronic disease management. Even single-digit gains can translate to significantly better health outcomes at a large scale.

- **Emerging real-world success:** Case studies from companies such as **Novartis** (AI-driven patient analytics), **Walgreens** (AI-personalized pharmacy outreach), and **GlaxoSmithKline** (GSK) (chatbot support for asthma/COPD) demonstrate measurable improvements in patient satisfaction and adherence. These examples prove that AI-driven engagement is delivering ROI and better care in practice, not just theory.

- **Regulatory compliance is paramount:** Adhering to **HIPAA, GDPR,** and **FDA** guidelines is critical for ethical and secure AI deployment. Pharma must navigate patient data privacy laws and ensure AI algorithms are transparent and fair to maintain patient trust and meet legal requirements.

- **Challenges exist but are surmountable:** Integrating AI with legacy **EHR** systems, addressing algorithmic bias, and ensuring interoperability are key hurdles. Successful programs marry advanced technology with thoughtful human oversight, robust data governance, and iterative model validation to overcome these challenges.

- **Emerging best practices:** Leading organizations optimize AI in patient support by focusing on quality data integration, cross-functional collaboration (IT, clinical, compliance teams), patient-centric design (inclusive of diverse patient needs), and continuous monitoring of outcomes and ethics. These ensure AI tools truly augment care and do so responsibly.

Pharmaceutical companies that strategically implement AI for patient engagement are seeing improved adherence, more efficient operations, and stronger patient relationships. As we explore in this whitepaper, the convergence of technology, data, and human-centered design in pharma's patient support programs is unlocking new value – but it requires navigating a complex landscape of technical and regulatory challenges. The journey is worth it; done right, AI-driven patient engagement can lead to measurably better health outcomes, empowered patients, and a sustainable competitive advantage in a healthcare market increasingly focused on experience and value.

Introduction

Patient engagement has become a cornerstone of pharmaceutical care, influencing medication adherence, treatment outcomes, and overall patient satisfaction. Yet traditional one-way engagement methods, such as pamphlets and call centers, have often fallen short of patient expectations. A recent survey of 2,000 healthcare consumers found that while **all healthcare business decision-makers** believed they were effectively engaging patients, only **35% of patients** felt valued by their providers. This discrepancy underscores the critical need for more effective, personalized engagement strategies. At the same time, poor patient adherence to therapy remains an endemic problem; each year, inadequate adherence is linked to over **$500 billion** in avoidable healthcare costs and around **125,000 preventable deaths** in the United States alone. These staggering figures highlight why keeping patients engaged in their treatment plans is not just nice-to-have, but life-saving.

Amid these challenges the pharmaceutical industry is turning to AI as a powerful solution for **patient-centric engagement**. Notably, the top 10 pharmaceutical companies in the world have all either collaborated with or acquired AI technologies, including giants like Novartis, Pfizer, Roche, and Johnson & Johnson, signalling a commitment across the industry to AI-driven transformation. AI promises to bridge the patient engagement gap by utilizing data and machine learning to deliver timely, personalized interventions. According to Rock Health, investment in digital health has consistently shifted toward pharma use cases, such as patient-facing digital therapeutics. Patients themselves are increasingly open to these innovations; nearly **50% of those surveyed** indicated that they are comfortable with doctors using AI to assist in their healthcare. In short, the stage is set for AI to redefine how pharma engages and supports patients.

This whitepaper explores the key aspects of this shift in detail. We begin by outlining the **technical foundations** of AI-driven patient engagement – the algorithms and digital infrastructure that make it possible. Next, we examine major **implementation challenges**, including compliance with health data regulations (HIPAA, GDPR), integration hurdles with electronic health records (EHRs), and concerns around algorithmic bias and transparency. We then delve into **real-world case studies** that illustrate how pharma and healthcare organizations are applying AI to improve patient engagement today – highlighting examples from **Novartis, GSK, Walgreens,** and others, as well as how AI is used in pharma-finance models like co-pay assistance programs. Finally, we discuss **best practices** for optimizing AI in patient support programs, gleaned from early adopters, to guide organizations on their journey toward more effective and ethical AI deployment.

By understanding both the opportunities and challenges presented by AI-driven patient engagement, pharmaceutical leaders can make informed decisions to harness these technologies responsibly. The ultimate goal is to enhance patient experiences and outcomes in a way that is scalable for the industry and sustainable for healthcare systems. In doing so, pharma companies not only improve the lives of patients but also solidify their evolving role as partners in the continuum of care.

Technical Foundations of AI-Driven Patient Engagement

Effective AI-driven patient engagement rests on two key pillars: **sophisticated AI/ML algorithms** and a **robust digital infrastructure**. Together, they enable what many experts call the "last mile" of healthcare delivery—ensuring that the right support reaches the right patient at the right time. In this section, we break down the core AI-driven strategies that pharma companies are deploying to personalize and improve patient interactions, and how these technologies work in practice.

Predictive Analytics for Adherence and Risk Stratification

Machine learning models (such as classification algorithms or ensemble methods like XGBoost) analyze historical patient data to predict which patients are **at risk of non-adherence** or complications. By flagging at-risk patients early, pharma-sponsored support programs or pharmacies can proactively intervene – for example, sending medication reminders, offering counselling, or alerting a healthcare provider to step in.

A practical example of this is **AllazoHealth's AI adherence solution**, which has been used in collaboration with Walgreens. This platform predicts each patient's probability of medication adherence and also determines **which type of intervention** (e.g., a text message versus a phone call from a pharmacist) would most effectively change that patient's behavior. The AI continuously learns and improves its accuracy over time by incorporating new data on what worked or didn't work, thereby optimizing targeting for better outcomes. In essence, predictive models like this function as an early warning system and triage tool: they not only identify who might need extra support but also recommend what kind of support is likely to be most effective.

The impact of such tailored predictive interventions can be significant. In the Walgreens case, an AI-driven adherence program led to measurable improvements in medication adherence across multiple chronic conditions. When comparing patients who received AI-personalized outreach to those who did not, adherence rates increased by **5.5% for hypertension medications, 8.6% for diabetes drugs, and 9.7% for cholesterol (statin) therapies**. These single-digit percentage improvements are clinically meaningful – even a small uptick in adherence can translate to fewer hospitalizations and better disease control across a large population. For example, better adherence in diabetes and hypertension management directly correlates with reduced complications and healthcare costs.

Thus, predictive analytics enable a shift from reactive to proactive care: rather than waiting for a lapse in adherence and potential health deterioration.

Personalized Communication via NLP and Chatbots

Another key strategy is using natural language processing (NLP) and conversational AI to scale personalized communication with patients. Modern NLP models, including large language models like Google's BERT, Microsoft's BioGPT, or fine-tuned versions of GPT-4, are now capable of understanding free-form patient queries and providing contextually relevant responses. Pharma companies and healthcare providers are deploying these models in the form of **chatbots** or voice assistants that can handle patient inquiries 24/7 with a surprisingly human-like touch.

These AI-driven chatbots serve as virtual health assistants. They can answer common questions about medications (e.g., "What should I do if I miss a dose?"), provide guidance on managing side effects, help schedule appointments or refills, and even offer basic motivational coaching. Critically, they do so in a manner that is empathetic and patient-friendly – something that early rule-based bots struggled with. Advances in NLP allow the chatbot to detect the sentiment or urgency in a patient's message and adjust its tone accordingly. Studies indicate that patients expect a courteous, **empathetic "bedside manner"** even from digital tools, and incorporating empathetic language into chatbot interactions has been shown to improve patient satisfaction and engagement.

For example, if a patient messages at 2 A.M. about a worrisome side effect, an AI assistant can instantly respond along the lines of, "I'm sorry you're experiencing that. It can be alarming, but please don't panic. Here's some information that might help..." and then provide actionable advice or triage steps. This immediate, always-on support reassures patients and lightens the load on healthcare providers by handling routine queries.

Pharmaceutical companies like **GlaxoSmithKline (GSK)** have piloted chatbot-based support for chronic disease patients. In one pilot, GSK used an NLP-powered chatbot to assist patients with asthma and COPD with proper inhaler technique and trigger management. The chatbot could answer FAQs and coach patients through exercises, and early reports indicated **higher patient satisfaction due to the 24/7 availability** of this virtual coach. The convenience of getting instant answers anytime – without waiting on hold for a call center or scheduling a pharmacist consult – is a game-changer for patient experience.

Other pharma giants such as Pfizer and Merck have also launched digital companion apps for some medications that incorporate chatbot features, blending AI monitoring of symptoms with patient education and even **gamified elements** to keep patients engaged. It's important to note that these

AI chatbots are typically designed to augment, not replace, human support.

They handle the frequent, low-complexity interactions and free up human clinicians or call center staff to focus on higher-level or sensitive issues. When a chatbot encounters a question it cannot confidently answer or detects signs of patient distress (e.g., mentions of severe symptoms or emotional cues), it will escalate to a human nurse or pharmacist. This "hybrid" model ensures that patients get the best of both worlds – efficiency and availability from AI, plus empathy and expertise from humans when needed.

The benefits of NLP-driven personalized communication are already evident. Patients get consistent answers and guidance, which reduces confusion and errors. They also tend to feel more supported throughout their journey, which can improve adherence and outcomes. From the pharma perspective, these tools (every patient gets reliable info aligned with drug guidelines) and allow support programs to scale to thousands of patients without a proportional increase in staff. Moreover, the conversational data collected (with patient consent) can feed insights – for instance, frequently asked questions might signal where patients commonly have knowledge gaps, prompting pharma to improve education materials or address misconceptions.

AI-Powered Recommendation Engines for Patient Support

Beyond reactive support and Q&A, AI is helping drive proactive engagement through recommendation engines. These are systems that analyze a variety of patient data to suggest the next best action or resource for that individual. In e-commerce, recommendation engines suggest products you might like; in healthcare, they suggest health interventions or educational content that could benefit the patient.

For example, a patient support program could use machine learning to mine datasets ranging from electronic health records and claims data to patient-reported outcomes and app data. By detecting patterns in how similar patients responded to certain interventions, the AI can recommend the most effective follow-up action for a given patient profile. If a patient is on a titration schedule for a new medication, the AI might personalize their dose-adjustment reminders and educational content based on what has worked for others with similar demographics and health conditions. In essence, these models act like **digital coaches**, continuously guiding patients in self-management.

One technique often used is **dynamic patient segmentation**. Instead of static categories (like age group or disease stage), clustering algorithms group patients by behaviors or risk factors – for instance, identifying a cohort of patients who tend to be late on refills and also have mobility issues. The system might learn that this cohort responds best to phone call reminders (perhaps because they are older and less responsive to texts).

Meanwhile, another segment might be tech-savvy and prefer push notifications through an app. Reinforcement learning algorithms can further optimize engagement tactics (timing, channel, messaging frequency) by continuously learning from patient responses – effectively personalizing not just what is communicated but how and when it's delivered. Pharma companies have begun implementing these AI-driven recommendation engines in areas like lifestyle coaching, dose optimization (with physician oversight), and adherence nudging. For instance, an AI might suggest a tailored educational module about diet and exercise to a patient with diabetes who's struggling with blood sugar control, based on the patient's recent glucose readings and activity data. Or it might alert a patient's nurse navigator that the patient hasn't logged into the support app for a while, prompting a check-in call. Novartis has invested in "Patient Analytics" projects that leverage partnerships with tech firms (like MIT, IBM, and McKinsey's QuantumBlack) to analyze real-world patient data and identify patterns to better support patients on treatment. Such projects use AI to crunch through large datasets to find actionable insights – for example, signals that a certain subset of patients is at high risk for dropping off therapy at month 3, triggering the development of a specific re-engagement plan for that window.

Overall, AI-driven personalization represents a leap beyond the traditional "one-size-fits-all" approach of patient support. It continuously adapts to each patient's journey, learning and iterating as more data is gathered. This means patient engagement is no longer but dynamic and responsive to individual needs. As one industry analysis summarized: AI allows providers and pharma teams to "more deeply engage patients in the right ways, fill care gaps, and nudge patients to improve their behavior – all without adding to provider workloads".

In short, AI is making engagement more efficient (scalable and automated) and more effective (tailored and timely).

Digital Infrastructure and EHR Integration

It's worth emphasizing that these AI capabilities require a strong **digital infrastructure** underneath. Data is the lifeblood of AI; hence, pharmaceutical companies are investing heavily in cloud computing, data integration platforms, and secure data pipelines to support AI-driven engagement at scale. Many organizations are moving away from siloed legacy systems and towards integrated data lakes that can aggregate diverse data streams – clinical data from EHRs, patient-generated data from apps and wearables, call centre logs, pharmacy refill data, etc.

By breaking down data silos, AI models can get a 360-degree view of the patient. "AI/ML models fed by big data (from EHRs, mobile devices, wearables, and more) represent the next frontier in patient engagement," as one report noted. This unified data approach allows algorithms to detect subtle patterns that might otherwise be missed. For example, noticing that a slight decline in a patient's physical activity (from their fitness tracker) coupled with a missed prescription refill could signal an early adherence issue or health setback.

Integration with **Electronic Health Records (EHRs)** is particularly crucial. When a pharma patient support program operates outside of the clinical EHR, there's a risk of fragmentation – doctors might not be aware of the support touches their patient is receiving, and support programs might lack the latest clinical updates. Leading programs are aiming for "closed-loop" integration, where insights from the AI system flow back to the clinician's or pharmacist's workflow.

For instance, if an AI algorithm identifies a patient at high risk of non-adherence, it might generate an alert or task in the provider's EHR or the pharmacist's system, prompting them to intervene during the next interaction. Likewise, if a physician changes a medication dose or notes a side effect in the EHR, the patient support AI could immediately adjust its recommendations and messaging. This kind of bi-directional data integration ensures that AI-driven insights lead to concrete actions in patient care, with the healthcare team in the loop.

To support such integrations and real-time analytics, cloud partnerships have become common. Pharma companies collaborate with cloud providers (AWS, Azure, Google Cloud) to leverage scalable infrastructure and advanced services like AI/ML platforms and secure data storage. For example, Merck's collaboration with Amazon Web Services helped create a **cloud-based analytics platform for patient data**, and Novartis's alliance with Microsoft established an **AI innovation lab to embed AI across operations.** Together, these technologies shift patient engagement from a static, reactive paradigm to a dynamic, proactive, and personalized one. However, implementing them in the real world comes with challenges – which we will explore next – including regulatory compliance and ensuring that the AI behaves ethically and safely in a healthcare context.

Implementation Challenges: Compliance, Integration, and Bias

While the promise of AI in patient engagement is compelling, implementing these technologies in the highly regulated pharmaceutical and healthcare environment is no simple task. Companies must navigate a host of challenges to ensure that AI tools are not only effective but also **compliant, interoperable, and equitable.** In this section, we discuss three major challenge areas: (1) **Regulatory compliance**, particularly with health data privacy laws like HIPAA and GDPR and guidance from the FDA; (2) **Integration with existing healthcare systems**, especially EHR interoperability and data quality issues; and (3) **Algorithmic bias and transparency**, ensuring AI does not inadvertently perpetuate disparities or unsafe recommendations.

Compliance with Health Data Regulations (HIPAA, GDPR, FDA)

Data privacy and security regulations are a paramount concern when deploying AI for patient engagement because these systems inevitably handle sensitive personal health information (PHI). In the United States, any initiative involving PHI must adhere to the **Health Insurance Portability and Accountability Act (HIPAA)**. HIPAA's requirements apply fully to AI just as they do to any other use of PHI – there are no special exemptions for fancy AI technology. This means pharma companies (if they are considered a covered entity or more often, working with covered entities) and their tech partners must implement all the required safeguards: use and disclose PHI only as permitted, ensure PHI is secured (e.g., encryption, access controls), and have business associate agreements in place when sharing data with AI vendors.

A primary consideration under HIPAA is determining the **permissible use of PHI for AI model training**. The HIPAA Privacy Rule allows PHI to be used for treatment, payment, or healthcare operations without patient authorization, but using PHI to develop an AI algorithm may not clearly fall under these categories. For example, if a pharma company wants to analyze patient data from a support program to improve its adherence prediction model, is that considered "healthcare operations" or is it research? Often it might be viewed as analysis beyond routine care operations, meaning explicit patient consent could be required unless a specific exception applies. In practice, obtaining individual authorizations from thousands of patients to use their data for AI can be logistically difficult and may slow down development. As a workaround, companies frequently de-identify data according to HIPAA standards (removing 18 types of identifiers) so that it's no longer considered PHI and can be used more freely for analytics and model training. Another approach is using a "limited data set" under a data use agreement or seeking an IRB waiver if the activity qualifies as research. The key is that any secondary use of patient data for AI has to be scrutinized under HIPAA's lens.

Beyond usage permissions, HIPAA's Security Rule mandates robust safeguards for any PHI handled by AI systems. This involves technical measures like encryption of data at rest and in transit, role-based access controls to ensure only authorized personnel or processes access the data and audit logging to track who or what is doing what with the data. With AI projects, an added complexity is that data scientists may need large datasets to develop and test models. Organizations address this by extending their access control policies to their AI development environments: only team members who truly need PHI for the project get access, and even then, they use the minimum necessary data. Some use techniques like data masking or synthetic data generation to allow algorithm development without exposing real PHI during early model training. The bottom line is that pharma companies treat HIPAA not just as a legal check-box, but as a framework for trust – patients must be confident that their data, when used to power AI engagement tools, is guarded with the same care as if it were in a doctor's office filing cabinet. Non-compliance is a non-starter, given both the hefty penalties and the incalculable damage to patient trust that could result from a breach.

In the European Union, the bar is arguably even higher due to the General Data Protection Regulation (GDPR). GDPR governs personal data use with an emphasis on individual rights and has strict requirements that directly impact AI projects. There is no ambiguity that patient data used for AI counts as "personal data" – GDPR absolutely applies to these healthcare AI scenarios. Key GDPR principles relevant to AI include lawfulness, transparency, data minimization, purpose limitation, and accuracy. Usually, companies will obtain explicit patient consent to process their health data for an AI-driven service, since using data for personalized engagement might exceed the original purpose of data collection (if not strictly for care). GDPR sets a high standard for consent – it must be informed (patients know exactly what they're consenting to), specific, freely given, and revocable. So patient support apps will include clear privacy notices explaining any AI-based profiling or decision-making, and give users the ability to opt out. Patients also have the right to withdraw consent later, which means companies must have mechanisms to delete their data or stop processing if asked.

GDPR also enshrines the right to transparency about automated decisions. Articles 13-15 give individuals the right to meaningful information about how their data is used, especially if there's automated decision-making or profiling involved. In practice, a pharma must disclose (perhaps in the app's privacy policy or even in-app messages) that an AI algorithm is being used to, say, adjust the frequency of engagement based on the patient's behavior. And importantly, GDPR Article 22 gives individuals the right not to be subject to a solely automated decision that has significant effects on them, unless certain conditions are met (such as explicit consent, or the decision is necessary for a contract or authorized by law). For patient support programs, this typically means any critical decision (like eligibility for a high-touch support tier or a financial assistance program) shouldn't be made by AI alone without human review. Or, if AI is used, patients might need an option to request human intervention or appeal the decision. These requirements push pharma to implement AI in a human-in-the-loop fashion in Europe – ensuring AI provides recommendations, but a human validates anything consequential, to stay on the right side of the regulation and ethics.

Finally, we have the role of the FDA and other health authorities in guiding AI use. The FDA has been increasingly active in issuing frameworks for AI in medical devices and software, which, while not all directly applicable to patient engagement tools (many of which are considered wellness or support tools rather than regulated medical devices), still influence best practices. If a pharma's AI tool crosses into functionality that might be seen as medical decision support or a diagnostic, FDA oversight could apply under software as a medical device (SaMD) rules. Even for unregulated support tools, the FDA encourages early consultation – pharma companies are advised to engage with the FDA early in development if their patient support AI might have any impact on treatment decisions, to ensure any regulatory concerns (safety, transparency, validation) are addressed in advance. The FDA in recent communications has stressed algorithm transparency and performance monitoring. For example, if an AI is recommending interventions, companies should have robust evidence of its safety and effectiveness in that context and put in place monitoring for real-world performance (to catch issues like model drift or biases). The FDA's stance is that AI can improve care but must maintain the same standards of safety and efficacy expected of more traditional interventions.

Notably, regulators globally are also zeroing in on algorithmic bias and fairness (which we'll discuss more below). An FDA subcommittee in 2022 examined how AI could either mitigate or exacerbate health disparities, signalling that future guidance might include expectations for bias testing and mitigation in healthcare AI. The emerging EU AI Act classifies many healthcare AI systems as "high-risk," imposing requirements like risk assessments, documentation, and human oversight for those systems. Pharma companies, especially those operating globally, are already preparing for these new rules.

In summary, the regulatory compliance landscape demands that pharma's AI-driven engagement programs be built with **privacy by design, transparency by design, and safety by design.** Compliance is not just about avoiding penalties; it's about building and maintaining **patient trust** – an critical currency if patients are to embrace AI-powered health tools.

Integration with EHRs and Legacy Systems

Another significant challenge in implementing AI for patient engagement is integrating these advanced tools into the **existing healthcare IT ecosystem.** Many pharma-led patient support programs run on separate platforms (patient apps, CRM systems for support reps, etc.), which need to exchange data with providers' electronic health records, pharmacy systems, and sometimes payer systems. Achieving seamless data flow between all these pieces can be technically complex but is essential for creating a unified patient experience and avoiding duplication or conflict in patient communications.

One hurdle is that health data is often siloed. A pharma might have data from its hub services (e.g., nurse call notes, patient enrolment info), while the physician's EHR has clinic visit notes and lab results, and the pharmacy has dispensing records. If these are not well-integrated, an AI might make recommendations on partial information. For instance, the AI could be reminding a patient to take a medication that the doctor has actually just discontinued or switched – simply because the AI's data feed wasn't updated with the latest order from the EHR. This underscores the need for real-time or near-real-time data integration. Modern integration approaches use APIs, HL7/FHIR standards, or middleware to let different systems talk to each other securely. A patient engagement platform might subscribe to certain event updates from the EHR (like medication changes or new lab results) and likewise send summaries back to the EHR.

Interoperability standards are improving, thanks to industry efforts and regulations (like the ONC's push for FHIR in the U.S.), but legacy systems can still pose challenges. Many EHRs were not designed with AI integration in mind and can require custom interfaces to ingest AI-generated recommendations or risk scores. Pharma companies often work with intermediaries or digital health integrators to handle these connections. It's an area where partnerships between pharma, providers, and health tech companies are critical – aligning on data formats, dictionaries (e.g., are we using the same definitions/codes for conditions and outcomes?), and workflows.

Data quality and consistency is another challenge. AI algorithms are garbage-in-garbage-out; if the data feeding them is incomplete or inaccurate, the output will suffer. Unfortunately, patient data in the real world can be messy – missing values, errors in records, or variability in how data is recorded by different clinics. Part of integrating AI means investing in data cleaning and normalization. Some pharma support programs do an initial data audit when onboarding a dataset (like claims or EHR extract) to understand its characteristics and address quality issues.

Increasingly, they use AI itself to help with this, such as employing NLP to reconcile differing terminology or machine learning to infer missing pieces (with caution).

Another integration aspect is fitting AI tools into **clinical workflows**. Even if data connectivity is solved, one must consider: how will healthcare professionals interact with these AI-driven insights. If a patient support AI flags a non-adherence risk, how does the care team know and act on it? In some cases, the pharma's patient support call center might handle it entirely. In others, they might send an alert to the prescribing doctor or the pharmacy. There needs to be a clear protocol; otherwise, you risk alert fatigue or confusion (e.g., the doctor thinking "Is someone already following up with this patient or should I?"). Several pilot programs have established joint protocols – e.g., the pharma's nurse navigator documents outreach in a system that the physician can view, or a note is added to the patient's EHR chart indicating enrolment in a support program.

Moreover, integration is not just technical but also process-oriented. Training staff to use new AI-driven tools, updating standard operating procedures, and ensuring accountability (who acts on an AI prompt) are part of change management. For example, if a chatbot escalates a chat to a human nurse, that nurse should have context of what the AI and patient discussed so far – which means designing the interface to show the conversation history and AI's reasoning if possible.

Addressing Algorithmic Bias and Ensuring Equity

One of the most discussed challenges with AI in healthcare is the risk of **algorithmic bias** – where the AI's outputs may be systematically less effective or even harmful for certain groups of patients, due to biases in the training data or design. In patient engagement, this could mean an AI system that works well for a typical patient profile but under-serves patients from minority backgrounds, for example, or those with atypical conditions.

Bias can creep in through many paths. If the data used to train an adherence prediction model is mostly from, say, urban populations with access to pharmacies, the model might not generalize well to rural patients who face different challenges (like transportation barriers). Similarly, if a chatbot's NLP engine wasn't trained on a diverse set of dialects and literacy levels, it might misunderstand or respond inappropriately to certain users, leading to frustration.

Inclusivity in data is therefore a key part of development. Pharma companies try to use data that reflects the diversity of their patient population or else explicitly acknowledge limitations and test the AI in different subgroups. As noted, GDPR's focus on data accuracy touches on this – accuracy isn't just correctness, but also that the data is representative to avoid bias. A model could be "accurate" on average but still perform poorly in an underserved group, which is not acceptable in a patient-centric approach.

To address bias, many organizations implement a few best practices:

- **Bias testing:** During validation, evaluate how the AI performs across different demographic slices (age, gender, race/ethnicity, etc.) and clinical characteristics. If disparities are found, adjust the model or data. For example, ensure an adherence model doesn't systematically under-predict adherence for one group due to socioeconomic factors unless appropriately contextualized.

- **Representative design:** Involve diverse patient input in the design of engagement content. For instance, ensure chatbot responses are culturally sensitive and available in multiple languages.

- **Human oversight:** Keep a human in the loop especially for sensitive decisions. The FDA and others have underscored that AI in healthcare should often serve as a support tool with human oversight. Humans can catch AI mistakes or biases on the fly. For example, if an AI outreach program surprisingly isn't engaging a certain community well, on-ground staff or patient feedback might catch that, prompting a review of the approach.

- **Continuous learning:** Deploy AI in a way that it can be improved with new data. If an AI system learns from ongoing interactions, ensure it has mechanisms to avoid locking in biases (some use techniques like reinforcement learning with fairness constraints).

Pharma also must consider **ethical AI principles**. Many companies (Novartis, for example) have published commitments to the ethical use of AI, emphasizing transparency, accountability, and fairness. Part of this is being clear to patients when AI is being used and what it's doing. It can be as simple as "Your support coach is an AI system designed to help you. Here's how it works...". Transparency builds trust and also helps patients correct the system ("Actually, that advice isn't relevant to me because...").

Ensuring equity also means thinking about access: not all patients have smartphones or are comfortable with digital tools. AI engagement strategies should be multimodal. For instance, an AI program might determine some patients would do better with a phone call or an in-person pharmacy consultation rather than an app notification. Bias can also be in assumptions that everyone can engage digitally – thus, a patient-centric AI program will intentionally include analog options (with AI perhaps assisting the human callers by prioritizing who to call).

It's encouraging that early studies show AI can potentially reduce disparities if done right – for example, the Walgreens AI adherence program naturally provided more support to socially vulnerable populations, improving their adherence, without being explicitly programmed to do so (the AI's personalization led it to devote extra attention where it was needed most). However, this is not guaranteed in every case and vigilance is needed.

Overcoming Challenges

Case in Point: To illustrate the interplay of these challenges, consider a **pharma-patient support program** for a new oncology therapy that uses AI to personalize patient education and adherence support:

- **Compliance:** Before launching, the program obtains patient consent that explicitly covers the AI-driven services (satisfying GDPR for EU patients and ethical best practices elsewhere). Data shared between the patient's cancer clinic and the pharma's support platform is de-identified when possible, and secured via encryption. Legal and IT teams ensure business associate agreements and data processing agreements are in place with any AI vendors. The program is careful not to cross into giving medical advice – it sticks to approved educational content – so as to not require FDA clearance, but they keep FDA informed as a protocol.

- **Integration:** The support platform is integrated with the oncology clinic's EHR via FHIR APIs. So when a patient's lab results come or a treatment cycle is delayed, the AI system knows and adjusts the support schedule. Nurses at the clinic can see a summary of the support interactions (like "patient received educational module on side-effect management on Jan 10") right in the EHR, avoiding any conflict or repetition. Conversely, if the patient calls the clinic with an issue, the AI system is updated so it doesn't redundantly send a generic follow-up message about that issue.

- **Bias & Equity:** The AI chatbot used for education has been trained on a dataset that included a wide range of patient questions (gleaned from patient focus groups and historical data), including minority and low-literacy populations. The content was reviewed by a diverse patient advisory panel. The program offers both a smartphone app and a telephone option – patients can speak to an AI assistant on the phone, ensuring even those without smartphones benefit. The team monitors engagement rates by demography and finds, for instance, older patients are using the service less. They respond by increasing training for those patients (having support staff proactively reach out to walk them through the app setup, for example).

This hypothetical illustration shows how careful planning and execution can mitigate many challenges: **designing for privacy, building interoperable systems, and baking in fairness and accessibility from the start**.

In short, implementing AI in pharma patient engagement is a cross-disciplinary endeavor. It's not just about data science; it's about **compliance officers, IT engineers, clinicians, and patient advocates working together**. Those companies that navigate these challenges successfully are not only creating innovative solutions but also setting new standards for trust and effectiveness in digital health. Next, let's look at some real-world case studies where these strategies and challenges come to life, illustrating lessons learned from early adopters.

Case Studies: AI in Action at Novartis, GSK, Walgreens, and Beyond

Let's explore:

- Novartis's use of AI for patient analytics,
- GSK's chatbot for respiratory patients,
- Walgreens' AI-powered adherence program, and
- How AI is being used in pharma-finance models for co-pay assistance.

Novartis: Patient Analytics and AI-Powered Support

Novartis, a global pharma leader, has heavily invested in AI across its business, including patient support. Novartis established an "AI innovation lab" in partnership with Microsoft, and collaborates with tech companies and research institutions (like MIT and QuantumBlack) on various AI projects. In the realm of patient engagement, Novartis has pursued advanced analytics to understand patient journeys and improve support interventions.

One notable effort is their use of AI to analyze **real-world patient data** from its support programs and potentially from broader sources (with permission). The goal is to identify patterns that can inform better support strategies. For example, by analyzing which patients tend to discontinue a therapy early, Novartis can tailor early interventions for future patients on those therapies. They might find that patients who lack frequent touchpoints in the first month drop off more, which led them to introduce a scheduled cadence of AI-driven check-ins via app or SMS for new starters. In a collaboration with an MIT analytics lab, Novartis used machine learning to sift through patient-reported outcomes and other data to detect subtle signals of when a patient's health might be declining, so that support could be offered promptly. While specific outcome metrics from these analytics initiatives are often kept internal, Novartis has reported generally that AI and data analytics are helping them shift to a more **data-driven, needs-based support model,** rather than a one-size-fits-all approach.

Another AI angle for Novartis is enhancing **clinical trial experiences** (which is tangentially patient engagement). They have explored digital companions for trial participants – an app with AI elements to guide patients through complex clinical trial protocols (e.g., reminders for taking investigational meds, reporting symptoms, etc.). The benefit is smoother trial conduct (patients better adhere to trial requirements) and a more positive experience for participants, making them feel cared for by an intelligent support system rather than left on their own between site visits.

Key takeaways from Novartis's approach: They illustrate the importance of partnerships and internal capacity-building for AI. By partnering with tech firms, they leverage external expertise and platforms, but they also build internal teams to operationalize insights. They focus on predictive analytics and "next best action" models that feed into their patient support workflows, ensuring that insights are actionable. Novartis's public stance on ethical AI indicates they are attentive to the trust aspect – for instance, they have guidelines to ensure AI is used transparently and with a clear patient benefit in mind.

GlaxoSmithKline (GSK): Chatbots for Respiratory Patient Support

GSK has been at the forefront of experimenting with digital engagement tools, especially in its respiratory franchise (as asthma and COPD management greatly benefit from ongoing patient education). GSK piloted an **AI chatbot** to assist patients using its inhalers for asthma and COPD. The chatbot, accessible via a mobile app or potentially through messaging platforms, could answer patient questions about inhaler usage, daily management of symptoms, and how to avoid triggers (like pollen or pollution). This was a strategic choice: inhaler technique is known to be a challenge for many patients, and improper use leads to suboptimal disease control. Traditionally, a patient might get a quick demo at the doctor's office or pharmacy, but then be on their own. GSK's chatbot filled that gap by being a **24/7 on-demand coach**.

Initial feedback from the pilot indicated that patients appreciated the constant availability and the non-judgmental nature of a bot. Some patients might feel embarrassed asking a human the same question multiple times, but with a chatbot, they could repeat or rephrase questions freely. GSK found that patient satisfaction was higher due to this "always-on" support, and it complemented human care – patients still saw their doctors, but between visits they had guidance. Additionally, data from the chatbot (appropriately anonymized) gave GSK insights into common pain points. For example, if many patients ask "What do I do if I feel jittery after using the inhaler?", that signals an educational opportunity about side effects management for the broader population.

From a compliance angle, GSK ensured the chatbot's content was **approved and consistent with medical guidelines**. The AI wasn't creating new answers on the fly (as generative AI would); rather it was using NLP to match questions to a knowledge base of vetted answers and instructions. This limited the risk of misinformation. It's a good example of how **conversational AI** in pharma often starts with a constrained approach (rules-based or retrieval-based chatbot) to maintain regulatory compliance, before moving to more advanced generative models in the future.

GSK's case highlights a broader point: **chatbots can effectively scale patient education for common, chronic conditions.** They reduce the burden on call centers and physicians for routine questions, ensure consistent messaging, and importantly, they can be updated centrally (if guidelines change or new FAQs emerge, the knowledge base is updated and every patient gets the updated info from then on). Best practices from GSK's experience include involving clinicians in designing the bot's content, testing it with real patients for usability, and making it a part of a multi-channel engagement strategy (the chatbot is one channel, but patients also got emails, plus the option to call a human nurse for complex issues).

Walgreens: AI-Powered Medication Adherence Program

Walgreens, as a large retail pharmacy chain, provides a compelling case study from the pharmacy side of the healthcare equation. In partnership with the AI company AllazoHealth, Walgreens implemented an AI-driven multichannel medication adherence program across its pharmacies.The aim was to improve patients' adherence to maintenance medications (like those for diabetes, hypertension, hyperlipidemia) by personalizing outreach based on each patient's situation and behavior.

Here's how it worked: Walgreens already had rich data on prescription fills and refills. The AllazoHealth AI platform ingested this along with other data (possibly demographic data, insurance type, and maybe even some social determinants data) **to predict which patients were at risk of not refilling on time or not taking medications properly.** For each patient, it would then determine the optimal intervention – for example, should the patient get a text reminder, an automated phone call, a live call from a pharmacist, or some combination – and even the timing of these messages (morning vs evening, etc.), based on what the model learned about that patient's responsiveness.

Over time, the AI "learned" preferences. Maybe Patient A tended to refill only after a phone call, whereas Patient B responded to a single text. So Patient A would be queued for a phone call outreach next month, and Patient B would just get the text. This is a stark contrast to the old approach where every patient gets the same reminder postcard or robocall. The AI essentially **micro-segmented** the patient population of Walgreens into thousands of "segments of one."

The results were impressive. As mentioned earlier, Walgreens reported increases in adherence: about **8.6% improvement for diabetes meds, 5.5% for hypertension, and 9.7% for statins** in the group receiving AI-personalized outreach versus a control group. These numbers, while single-digit, are meaningful at scale. Walgreens and AllazoHealth noted that such adherence gains could lead to better health outcomes (e.g., fewer complications or hospital visits) and also benefit Walgreens' own quality metrics (pharmacies in the U.S. are often rated on quality measures including adherence rates for chronic meds). Another insightful finding was that the program did **not exhibit bias in support** – in fact, it naturally tended to provide more support to patients in more disadvantaged areas, since those patients often had lower baseline adherence and thus the model allocated more resources to them.

This is an example of AI potentially helping to allocate healthcare resources in a way that addresses disparities, though careful oversight is needed to ensure fairness. For Walgreens, a key to success was integrating AI into pharmacy workflow. The AI would generate recommendations that seamlessly translated into action – e.g., it might populate a list for pharmacy staff of "here are the 50 patients you should call today and here's what to focus on for each." Or automatically trigger texts for others. Embedding these into routine processes, ensured the insights were acted upon. The program also had to be conscious of **compliance with communication preferences and privacy** (e.g., only texting if the patient opted in, including necessary disclaimers, and protecting patient data when using a vendor's AI cloud service through a business associate agreement).

The Walgreens case study underscores ROI – they could directly measure improved adherence and likely saw improved customer loyalty (a patient who feels cared for is more likely to stay with that pharmacy). It's a template that other pharmacies and hub service providers are now following, where **predictive analytics + tailored multi-channel outreach** become standard for patient support programs.

AI in Pharma-Finance Co-pay and Patient Assistance Programs

Patient engagement isn't only about clinical support; it's also about helping patients navigate the often convoluted financial aspects of therapy. Pharma companies spend billions on **co-pay assistance and patient assistance programs** to ensure cost isn't a barrier for patients to stay in therapy. Here too, AI is making inroads – both to ensure eligible patients get the help they need (increasing uptake of assistance) and to prevent misuse or fraud in these programs, which can be costly.

Consider that the pharma industry spends at least **$12 billion a year on co-pay programs** in the U.S. alone. These programs help cover patients' out-of-pocket costs for medications, especially high-cost drugs. With such scale, issues have arisen: some pharmacies or bad actors have defrauded co-pay systems, and some patients who need help still fall through the cracks because the system is so complex.

AI is being applied in a couple of ways:

- **Detecting Fraud and Abuse:** Firms like ZS Associates have worked with pharma to use AI on co-pay claim data to spot patterns of potential fraud. For instance, if certain pharmacies show anomalous patterns (e.g., extremely high rejection rates from insurers but then immediately using co-pay cards, or multiple claims that max out the co-pay benefit in suspicious ways), an AI can flag those for investigation. In one case, analysis uncovered a network of pharmacies conspiring to exploit co-pay cards for fake prescriptions. Traditional audits might miss such patterns or catch them late; AI can sift through millions of transactions quickly to find outliers. By mitigating this "revenue leakage," pharma can ensure the funds go to real patients in need, and reduce losses that ultimately impact how much support they can offer overall.

- **Optimizing Patient Access and Enrolment:** On the flip side, many patients struggle to navigate the labyrinth of financial assistance – there are co-pay cards, foundation grants, and free drug programs, each with their own forms and criteria. Startups like **Atlas Health** and **TailorMed** use AI to streamline patient financial navigation. Atlas Health noted that about **$30 billion in potential healthcare aid goes unclaimed each year** because patients and providers either don't know about it or can't manage the paperwork. Their AI scours a patient's insurance info, medical bills, and personal data to match them with relevant programs (like a particular cancer drug patient assistance program or a foundation that helps with travel costs). AI prioritizes which patients likely qualify and should be reached out to first, and even automates parts of the application process. TailorMed's AI, for instance, can identify, say, all patients scheduled for an expensive treatment next month who have high deductibles and flag them for the financial counselor, suggesting which co-pay or charity programs could help.

By **proactively connecting patients to assistance**, these tools improve therapy initiation and adherence – a patient who might have abandoned treatment due to cost can continue because they got support. For pharma, it means the support programs fulfill their purpose (helping real patients, which also translates to the intended medication usage). There is also a trend of using predictive analytics to adjust co-pay program design – e.g., predicting how changes in benefits (like raising the max co-pay coverage) might impact adherence or persistence, and thus optimizing the program parameters for both patient benefit and business sustainability.

Case example: A leading pharma partnered with an AI firm to reduce co-pay card fraud and found that within months they identified over 150 pharmacies that were misusing co-pay cards, potentially saving $50 million in fraudulent claims. This allowed them to redirect funds to genuine patient needs. On the patient side, a health system using TailorMed's platform was able to increase the number of patients getting financial help, with the AI effectively **triaging financial risk** among their patient population and guiding the staff to intervene early (for example, contacting a patient before they fail to pick up a prescription due to cost, rather than after).

This domain shows that patient engagement isn't just clinical reminders – it's holistic, covering financial well-being as well. AI supports what's sometimes called "**patient financial navigation**," which is increasingly recognized as part of the patient experience, given how stressful and confusing medical bills can be. By reducing that burden, patients can focus more on their health.

Best Practices and Lessons

- **Start with a focused problem and measure outcomes:** Each initiative targeted a clear pain point (improper inhaler use, medication non-adherence, co-pay fraud, etc.) and defined metrics for success (satisfaction scores, % adherence increase, dollars saved or aid delivered). Clear focus and KPIs help demonstrate value and learn what works.

- **Iterate and learn:** The AI systems were not set-and-forget. Walgreens' program, for instance, continuously learned from patient responses to improve. GSK likely refined its chatbot based on patient feedback. A/B testing different approaches and iterating is key in these early stages of AI in engagement.

- **Integrate into workflow:** All cases integrated AI outputs into existing human workflows (pharmacists' calls, financial counselor processes, etc.) or into patient workflows (like an app they were already given). This integration is crucial so that AI doesn't become a parallel silo.

- **Maintain human touch:** Each program kept humans in the loop for high-touch needs. The chatbot escalates to human support for complex questions; the Walgreens program ultimately results in a human call for some patients as determined by AI; financial AI tools direct human counselors to help patients apply for aid. This hybrid approach builds trust and effectiveness.

- **Ensure compliance and ethics from the get-go:** These initiatives paid attention to data use permissions and fairness. They also communicated value to stakeholders (e.g., pharmacists trusted the AI because it was rolled out with training and showed clear improvement in their store metrics, and patients trusted the chatbot because it was branded, vetted, and introduced properly as a support tool).

As we look at these case studies collectively, a common thread emerges – successful programs marry advanced **AI technology with thoughtful deployment in patient-friendly ways.** They measure success not just in clicks or app usage, but ultimately in improved health outcomes and patient well-being. Moreover, they share a collaborative spirit: pharma works with tech companies, pharmacies, providers, and even patients to design solutions that truly address needs. The breadth of these initiatives across top organizations reinforces that AI-driven patient engagement is no longer a niche experiment; it's becoming a **mainstream strategy** in healthcare.

Pharma executives are increasingly confident that these pilots will scale into broader programs impacting millions of patients. As one leader anticipated, many pilot programs (from AI "nurse" chatbots to predictive adherence platforms) could grow into "multi-billion dollar programs in the next 3-5 years," given their early success and the significant unmet needs they address.

Conclusion

The path to AI-driven patient engagement is a journey requiring strategy, vigilance, and empathy.

Pharma companies that follow these best practices are positioning themselves not only to achieve better metrics (like higher adherence or efficiency) but to genuinely enhance the **patient experience**. And that is ultimately the heart of patient engagement – making each patient feel supported, heard, and empowered in managing their health.

As we look ahead, the landscape will continue to evolve with new technologies and trends. Future trends and emerging technologies are posited to further revolutionize patient engagement and healthcare at large – from the metaverse and virtual trials to generative AI and blockchain. These hold exciting possibilities for the next era of digital health, and pharma companies have a pivotal role to play in harnessing them responsibly. The future is coming fast, and organizations that combine innovation with thoughtful implementation will lead the way.

References

*AllazoHealth(2021). AI-Driven Impact: Boosting Medication Adherence at Walgreens – Case Study (8.6%↑ diabetes, 9.7%↑ statins adherence with AI outreach).

*HIPAA Privacy Rule (45 CFR §164) – Use of PHI for AI must align with TPO or require authorization; de-identification common for AI development.

*GDPR (2016) – Explicit consent, transparency (Art. 13-15), and rights (Art. 22) apply to AI profiling in patient support; 70%+ health execs using metaverse tech (BCG, 2023).

*Pharma Industry Report (2024) – "AI/ML fed by big data from EHRs, wearables represent next frontier in patient engagement," integration via cloud partnerships (Merck-AWS, Novartis-Microsoft)

.

*AllazoHealth (2021). Walgreens AI Adherence Case – Personalized comms yielded +5.5% to +9.7% adherence gains by condition, demonstrating real-world impact.

*PharmaVoice (2019). The Uptick in AI Use – Top 10 pharma all invested in AI; Novartis partnering with MIT, IBM, and QuantumBlack for patient analytics and drug discovery AI.

*ZS Associates (2021). Mitigating Co-Pay Fraud – Pharma spends $12B+ on co-pay; AI flags anomalous pharmacy patterns ($7M fake claims, Detroit $46M ring) to save millions.

*Rose, J.Z. (2022). Medication Adherence Not Zero-Sum (AJMC) – Poor adherence → $500B avoidable costs, ~125k preventable U.S. deaths annually, underscoring engagement importance.

(Additional sources and citations are integrated as hyperlinked references throughout the text.)

About Altimetrik

Altimetrik is a pure-play digital business services company focused on deliveringmeasurable business outcomes through an agile, product-oriented approach. Our industry-first, proven digital business methodology serves as a blueprint to develop, scale, and launch new products to market faster. With a team of over 6,500+ practitioners skilled in software, data, and cloud technologies, we foster an agile engineering culture that drives collaboration, innovation, and modernization. By delivering results in incremental, bite-sized phases, Altimetrik helps businesses build new models and achieve transformation without disruption, serving as a strategic partner and catalyst for growth. The company has recently been recognized as a Product Challenger in ISG's prestigious Provider Lens™ 2024 study on Advanced Analytics and AI Services in the U.S. region.